Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, phase III trial to evaluate the efficacy and safety of HIV vaccine [Biosantech] in patients with HIV infections

Next Previous
Trial Profile

A prospective, phase III trial to evaluate the efficacy and safety of HIV vaccine [Biosantech] in patients with HIV infections

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV vaccine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use

Most Recent Events

  • 18 Mar 2016 New trial record
  • 15 Mar 2016 According to Biosantech media release, based on the results of its IIa trial (see CTP700229617), the company will put forward request for this phase III trial of its anti-HIV vaccine for an extensive evaluation during 2016. Subject to approval by the regulatory authorities and the results of this trial, an initial anti-HIV vaccine would be available from the H2 of 2018. The company intends to request a MAA for its anti-HIV vaccine in second half of 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top